SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Providing Computational Insights into Cardiac Xenotransplantation

XENOSIM aims to advance cardiac xenotransplantation by developing high-resolution simulations to understand porcine heart compatibility and improve surgical outcomes.

Subsidie
€ 1.999.410
2024

Projectdetails

Introduction

We are at the dawn of a new age in medicine, marked by the first pig-to-human heart transplant. Xenotransplantation has long been a dream for clinicians and now, due to rapid progress in gene editing, is becoming a reality.

Challenges in Xenotransplantation

To overcome immediate rejection, barriers of immunity and infection have to be addressed. However, achieving long-term success requires a deep understanding of the physiological and mechanical challenges introduced by the anatomically dissimilar xenotransplants.

Objectives of XENOSIM

XENOSIM aims to address these challenges by providing fundamental clinical insights into the nascent field of cardiac xenotransplantation through the development and application of novel high-resolution, higher-order, multiphysics simulation methods.

Current Limitations

Tremendous progress has been made in biomedical imaging; nonetheless, a multitude of physical phenomena relevant to xenotransplantation are not available for experimental observation. In silico studies are uniquely placed to provide insights into the haemodynamic disruption caused by replacing a human heart with an anatomically dissimilar one.

Development of Porcine Cardiac Xenotransplant Models

XENOSIM is targeting the establishment of the first family of porcine cardiac xenotransplant models that can provide clinically significant insights into:

  1. The haemodynamic compatibility of porcine donor hearts
  2. The impact of surgical approach
  3. The consequence of pathologies

To provide these novel insights requires new coupled simulation approaches.

New Simulation Methods

Accordingly, the second goal of XENOSIM is to create a new class of monolithic finite volume fluid-electro-solid interaction methods, which can provide predictions in clinically relevant timescales through the exploitation of hybrid CPU-GPU systems.

Impact of XENOSIM

XENOSIM will establish the new field of computational cardiac xenotransplantation. Furthermore, the novel numerical methods established by XENOSIM are expected to impact a broad range of fields well beyond the project end.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.410
Totale projectbegroting€ 1.999.410

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINpenvoerder

Land(en)

Ireland

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

ERC Advanced...€ 2.500.000
2023
Details

Using CARDIac simulations to run in-silicO clinical TRIALS

This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.

ERC Starting...€ 1.499.423
2022
Details

Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs

G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.

ERC Starting...€ 1.497.351
2022
Details

Surgical optogenetic bioprinting of engineered cardiac muscle

LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.

ERC Starting...€ 1.499.705
2023
Details

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease

The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.

ERC Starting...€ 1.496.395
2022
Details
ERC Advanced...

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

ERC Advanced Grant
€ 2.500.000
2023
Details
ERC Starting...

Using CARDIac simulations to run in-silicO clinical TRIALS

This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.

ERC Starting Grant
€ 1.499.423
2022
Details
ERC Starting...

Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs

G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.

ERC Starting Grant
€ 1.497.351
2022
Details
ERC Starting...

Surgical optogenetic bioprinting of engineered cardiac muscle

LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.

ERC Starting Grant
€ 1.499.705
2023
Details
ERC Starting...

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease

The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.

ERC Starting Grant
€ 1.496.395
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

ADAM-X-Heart

Utrecht Preclinical en Medical-X ontwikkelen ADAM-X-Heart, een proefdiervrije simulator voor hartchirurgische training, om de kwaliteit, capaciteit en kosten van opleidingen te verbeteren.

Mkb-innovati...€ 329.735
2021
Details

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder€ 4.475.946
2022
Details

High-throughput ultrasound-based volumetric 3D printing for tissue engineering

SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.

EIC Pathfinder€ 2.999.625
2025
Details

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition€ 1.457.500
2023
Details

Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.

SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.

EIC Transition€ 786.875
2022
Details
Mkb-innovati...

ADAM-X-Heart

Utrecht Preclinical en Medical-X ontwikkelen ADAM-X-Heart, een proefdiervrije simulator voor hartchirurgische training, om de kwaliteit, capaciteit en kosten van opleidingen te verbeteren.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 329.735
2021
Details
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

EIC Pathfinder
€ 4.475.946
2022
Details
EIC Pathfinder

High-throughput ultrasound-based volumetric 3D printing for tissue engineering

SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.

EIC Pathfinder
€ 2.999.625
2025
Details
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

EIC Transition
€ 1.457.500
2023
Details
EIC Transition

Simultaneous Multiparametric MEA based platform for in-vitro chronic cardiotoxicity assessment with live-cell fluorescence imaging and electrophysiology.

SiMulTox develops a novel platform for simultaneous long-term assessment of functional and structural cardiotoxicity, aiming to enhance drug safety evaluation and reshape the in-vitro testing market.

EIC Transition
€ 786.875
2022
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.